News
SNYNF
83.68
NaN%
--
Sanofi (SNYNF) Receives a Buy from Deutsche Bank
TipRanks · 21h ago
Weekly Report: what happened at SNYNF last week (0921-0925)?
Weekly Report · 1d ago
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Seeking Alpha · 5d ago
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
TipRanks · 09/21 14:16
Weekly Report: what happened at SNYNF last week (0914-0918)?
Weekly Report · 09/21 09:46
Itepekimab COPD Extension Trial Completion: What It Means for Regeneron and Sanofi
TipRanks · 09/18 16:30
U.S. weighs allowing most pharma licensing deals with China, Reuters says
TipRanks · 09/18 14:40
Trump administration is said to weigh allowing most pharma licensing deals with China
Seeking Alpha · 09/18 11:08
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 09/17 18:21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Amgen (AMGN) and BrightSpring Health Services, Inc. (BTSG)
TipRanks · 09/17 11:30
Sanofi inaugurates Canadian flu vaccine faclity
TipRanks · 09/16 14:35
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive
Seeking Alpha · 09/16 09:18
RBC Capital Keeps Their Hold Rating on Sanofi (SNYNF)
TipRanks · 09/15 01:46
Sanofi Deepens Cheplapharm Tie-Up in Major Mature Medicines Shift
TipRanks · 09/14 13:38
Sanofi, Cheplapharm enter strategic partnership
TipRanks · 09/14 13:26
Weekly Report: what happened at SNYNF last week (0907-0911)?
Weekly Report · 09/14 09:48
Deutsche Bank Sticks to Its Buy Rating for Sanofi (SNYNF)
TipRanks · 09/14 08:55
Sanofi Updates Share Capital and Voting Rights Structure for August 2026
TipRanks · 09/11 17:02
Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside
TipRanks · 09/11 16:30
Dupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi
TipRanks · 09/11 16:30
More
Webull provides a variety of real-time SNYNF stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNYNF
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.